Interview with Dr Peter A Kaufman

Article

Dr Peter A Kaufman, discussed the promising activity demonstrated by motesanib in a small phase 1b trial of women with locally recurrent, unresectable, or metastatic breast cancer.

Dr Peter A Kaufman, Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, discussed the promising activity demonstrated by motesanib in a small phase 1b trial of women with locally recurrent, unresectable, or metastatic breast cancer.

MP3 DOWNLOAD: PETER_KAUFMAN.mp3

(Right click to download podcast)

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
© 2024 MJH Life Sciences

All rights reserved.